Latest Insider Transactions at Sangamo Therapeutics, Inc (SGMO)
This section provides a real-time view of insider transactions for Sangamo Therapeutics, Inc (SGMO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SANGAMO THERAPEUTICS, INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SANGAMO THERAPEUTICS, INC's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 25
2021
|
James R Meyers |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
Feb 25
2021
|
H Stewart Parker |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+20.81%
|
-
|
Feb 25
2021
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+26.11%
|
-
|
Feb 25
2021
|
Karen L. Smith |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+24.19%
|
-
|
Feb 25
2021
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,200
+14.54%
|
-
|
Feb 25
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
BUY
Grant, award, or other acquisition
|
Direct |
138,375
+28.51%
|
-
|
Feb 25
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
35,311
-14.47%
|
$388,421
$11.19 P/Share
|
Feb 25
2021
|
Gary Loeb EVP, General Counsel & Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+33.14%
|
-
|
Feb 25
2021
|
Gary Loeb EVP, General Counsel & Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
5,762
-11.4%
|
$63,382
$11.19 P/Share
|
Feb 25
2021
|
David Mark Mc Clung EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+22.22%
|
-
|
Feb 25
2021
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+28.94%
|
-
|
Feb 25
2021
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
7,779
-11.79%
|
$85,569
$11.19 P/Share
|
Feb 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,750
+25.05%
|
-
|
Feb 25
2021
|
Prathyusha Duraibabu SVP, CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,863
-6.37%
|
$20,493
$11.19 P/Share
|
Feb 12
2021
|
Robert J. Schott SVP, Head of Development |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
Jan 24
2021
|
Sandy Macrae PRESIDENT, CEO AND DIRECTOR |
SELL
Payment of exercise price or tax liability
|
Direct |
3,977
-1.6%
|
$55,678
$14.95 P/Share
|
Dec 31
2020
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Open market or private sale
|
Direct |
2,464
-3.6%
|
$39,424
$16.74 P/Share
|
Dec 24
2020
|
Rolf Andrew Ramelmeier EVP, Technical Operations |
SELL
Open market or private sale
|
Direct |
3,331
-4.64%
|
$59,958
$18.13 P/Share
|
Dec 17
2020
|
Saira Ramasastry Director |
SELL
Open market or private sale
|
Direct |
10,000
-40.0%
|
$130,000
$13.27 P/Share
|
Dec 17
2020
|
Saira Ramasastry Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+28.57%
|
$50,000
$5.99 P/Share
|
Nov 25
2020
|
Sung Lee EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,042
-5.38%
|
$45,378
$9.77 P/Share
|